Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis
Open Access
- 27 March 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 20 (1), 1-12
- https://doi.org/10.1186/s12879-020-04973-0
Abstract
Treatment of resistant Pseudomonas aeruginosa infection continues to be a challenge in Latin American countries (LATAM). We synthesize the literature on the use of appropriate initial antibiotic therapy (AIAT) and inappropriate initial antibiotic therapy (IIAT) in P. aeruginosa infections, and the literature on risk factors for acquisition of resistant P. aeruginosa among hospitalized adult patients in LATAM. MEDLINE, EMBASE, Cochrane, and LILAC were searched between 2000 and August 2019. Abstracts and full-text articles were screened in duplicate. Random effects meta-analysis was conducted when studies were sufficiently similar. The screening of 165 citations identified through literature search yielded 98 full-text articles that were retrieved and assessed for eligibility, and 19 articles conducted in Brazil (14 articles), Colombia (4 articles), and Cuba (1 article) met the inclusion criteria. Of 19 eligible articles, six articles (840 subjects) examined AIAT compared to IIAT in P. aeruginosa infections; 17 articles (3203 total subjects) examined risk factors for acquisition of resistant P. aeruginosa; and four articles evaluated both. Four of 19 articles were rated low risk of bias and the remaining were deemed unclear or high risk of bias. In meta-analysis, AIAT was associated with lower mortality for P. aeruginosa infections (unadjusted summary OR 0.48, 95% CI 0.28–0.81; I2 = 59%), compared to IIAT and the association with mortality persisted in subgroup meta-analysis by low risk of bias (3 articles; unadjusted summary OR 0.46, 95% CI 0.28–0.81; I2 = 0%). No meta-analysis was performed for studies evaluating risk factors for acquisition of resistant P. aeruginosa as they were not sufficiently similar. Significant risk factors for acquisition of resistant P. aeruginosa included: prior use of antibiotics (11 articles), stay in the intensive care unit (ICU) (3 articles), and comorbidity score (3 articles). Outcomes were graded to be of low strength of evidence owing to unclear or high risk of bias and imprecise estimates. Our study highlights the association of AIAT with lower mortality and prior use of antibiotics significantly predicts acquiring resistant P. aeruginosa infections. This review reinforces the need for rigorous and structured antimicrobial stewardship programs in the LATAM region.Keywords
Funding Information
- Merck Sharp and Dohme (NA)
This publication has 34 references indexed in Scilit:
- Clinical and microbiological characterization of pneumonia in mechanically ventilated patientsThe Brazilian Journal of Infectious Diseases, 2012
- Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapyThe Brazilian Journal of Infectious Diseases, 2012
- Factors associated with epidemic multiresistant Pseudomonas aeruginosa infections in a hospital with AIDS-predominant admissionsThe Brazilian Journal of Infectious Diseases, 2012
- Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream InfectionsAntimicrobial Agents and Chemotherapy, 2012
- Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: Risk factors and mortalityJournal of Critical Care, 2009
- Controlling the Clonal Spread ofPseudomonas aeruginosaInfectionInfection Control & Hospital Epidemiology, 2008
- Risk Factors for Recovery of Imipenem- or Ceftazidime-Resistant Pseudomonas aeruginosa Among Patients Admitted to a Teaching Hospital in BrazilInfection Control & Hospital Epidemiology, 2006
- Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case–control studies in hospitalized patientsJournal of Hospital Infection, 2005
- Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?Clinical Infectious Diseases, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986